The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/insilico-brings-ai-skills-to-coronavirus-therapy-search-prepares-for-ipo-58074375 apologies if I've posted this before but it's of some interest in light of heimdal's comments. 10 months ago Zhavoronkov talked about possibly IPOing on the HK or Shanghai markets. personally i don't think there is any chance of regent being involved.i doubt Zhaovoronkov would regard a company with regent's less than impressive record as being a suitable vehicle to have any direct involvement.furthermore i suspect strongly that he is not a mellon minion and would probably not welcome too much reliance on a mellon vehicle. that said i do in a sense share your optimism,heimdal.i suspect insilco is going places and will probably go down a formal ipo route, as it will no doubt require considerable financing. regent may derive some peripheral benefit in some way (this is just a rather nebulous thought) as there may be some cross fertilisation with DLI. i would hope that Zhavoronkov will continue for some time as DLI's CLO, as he does seem to have considerable interest and reputation in the longevity field. if he does and insilico does float, we may perhaps benefit by association. not wishing to harp on about it, but i do expect a further acquisition in the longevity sphere during the year .to me it makes no sense just to have DLI in the stable on its own, but I'm just musing .do real ideaof course.incidentally i think jamie is still no two shareholder. zhavoronkov has the number of shares you mention heimdal but his percentage is, i believe,3.35%. what is worth noting,imo,i that there are a number of associated parties with interests in DLI and longevity generally, who have holdings as well as Zhavoronkov. the two insilco companies have 4.63 %, wei-wu-he and mamoshina have almost 2% between them and there are a couple of other longevity funds or similar with another 2.46%.what it means for regent's future is anyones guess.
Apols,
Of course I meant the DBC (the DBS is a bank in Singapore). Age is certainly catching up with me.....lol
Gushing should have been guessing...... Although they are gushing with BS.........lol
Obviously time will tell, but I am not going to hold my breath about the DLI until shareholders have been provided with a proper detailed road map/business plan on how DLI will make money for the company and not just speculation on links with InSilico which has its own AI.
Heimdal,
You could be right, however. The board also said the same about the DBS and look what happened to that. Unfortunately, you know as well as me that the board know absolutely SFA about anything to do with pharma and are gushing and following orders.
Thank you Bothwell. I think we are very fortunate to have Dr Alex Zhavoronkov onboard as CLO at DLI.
Insilico is clearly world class in terms of AI based drug research and discovery. As a world first, Insilico discovered
a novel biological target and generated a novel small molecule for Idiopathic Pulmonary Fibrosis, which around 5,000,000 people suffer from around the world. Once diagnosed with IPF you only have abot four years to live, so this new discovery is really fantastic news. I am sure more discoveries will follow.
I noted on LinkedIn (where Insilico have 6,450 followers) that they are dedicated to taking this and several other programs into clinic, and are ready to partner with other companies on delivering new therapeutic programs into advanced stages for diseases of interest. This might well be an opportunity for Regent Pacific to work hand in hand with Insilico in this new and exciting field. After all it was recently clearly stated that "the Board believes that the acquisition of DLI will add a high-quality growth asset to the Company, which will serve as a key platform for its expansion into the health and wellness sector, (namely the emerging field of longevity medicine). M e d i c i n e! Insilico is still unlisted whereas Regent Pacific is well placed on the HKSE and could easy raise funds for collaboration with Insilico. Longer term I wonder if Jim and Jamie would consider snapping up Insilico altogether? Alex is already Regent Pacific's second largest share holder with 75.7m shares. Will be interesting to see how this plays out.
Heimdal
Heimdal
Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, said: “Can AI design a novel molecule for a novel target that has no known inhibitors and has not been validated in a disease? And now we have successfully linked both biology and chemistry and nominated the preclinical candidate for a novel target, with the intention of taking it into human clinical trials, which is orders of magnitude more complex and more risky problem to solve.
Insilico
ISM001: Progress at a GlanceFibrosis Target ID, Compound Generation and Validation in <18 months. Source: Insilico Medicine
To my knowledge this is the first case where AI identified a novel target and designed a preclinical candidate for a very broad disease indication. It is a major milestone for us as our ultimate moonshot is to go after senescence and we need to have many enabling AI technologies that help us understand and manipulate human biology in other chronic diseases.”
Insilico
Potent target inhibition of ISM018_055. Source: Insilico Medicine
The company also announced the formation of a team of over 20 expert drug hunters and drug developers in Shanghai led by Dr Feng Ren, former senior VP of biology and chemistry at Medicilon, and former head of chemistry at GSK, who joined Insilico in February as chief science officer. This team will be responsible for taking the AI-discovered drugs into human clinical trials and creating a broad portfolio of preclinical assets.
And we are currently down 6% with huge news on both fronts.... Strange is the mind of the Asian investor.
Bignose, the market is down almost 900 points (or 3%) today...
Apparently not. The SP just dropped 3.85%
But will it impact the DLI whos staff work in a different office... :-O
They have found a new Starbucks just around the corner from the office which will reduce the time it takes for our staff to buy their coffee and hence be able to spend more time in the office working....... LOL
"We have a HUGE #announcement coming up TODAY! We will be announcing the biggest #breakthrough Insilico Medicine has ever made. We have reached a very important milestone that will have a great potential effect on future drug discovery.
Stay tuned! #insilicomedicine #news #AI #drugdiscovery #artificialintelligence #biomarkers #biotechnology #biology #science #health #healthcare #medicinalchemistry #research"